Piramal Pharma Limited

NSE PPLPHARMA.NS

Piramal Pharma Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2024: USD -50.64 M

Piramal Pharma Limited Net Cash Used Provided By Financing Activities is USD -50.64 M for the year ending March 31, 2024, a -150.89% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Piramal Pharma Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2023 was USD 99.50 M, a -16.59% change year over year.
Piramal Pharma Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2022 was USD 119.29 M, a -80.56% change year over year.
Piramal Pharma Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2021 was USD 613.77 M.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NSE: PPLPHARMA.NS

Piramal Pharma Limited

CEO	Mr. Peter Daniel DeYoung
IPO Date	Oct. 19, 2022
Location	India
Headquarters	507, Skyline Wealth Space
Employees	6,719
Sector	Healthcare
Industries Drugstores & Retail Pharmacies Cleaning Supplies Cosmetics Eyewear Non-Alcoholic Beverages Perfumes & Fragrances Personal Care Pharmaceuticals

Description

Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India. Piramal Pharma Limited operates as a subsidiary of Piramal Enterprises Limited.

Key trends

Past 5 years